207 related articles for article (PubMed ID: 29748210)
21. Topoisomerase I activity and sensitivity to camptothecin in breast cancer-derived cells: a comparative study.
Tesauro C; Simonsen AK; Andersen MB; Petersen KW; Kristoffersen EL; Algreen L; Hansen NY; Andersen AB; Jakobsen AK; Stougaard M; Gromov P; Knudsen BR; Gromova I
BMC Cancer; 2019 Nov; 19(1):1158. PubMed ID: 31783818
[TBL] [Abstract][Full Text] [Related]
22. Design, synthesis, and biological evaluation of cytotoxic 11-alkenylindenoisoquinoline topoisomerase I inhibitors and indenoisoquinoline-camptothecin hybrids.
Fox BM; Xiao X; Antony S; Kohlhagen G; Pommier Y; Staker BL; Stewart L; Cushman M
J Med Chem; 2003 Jul; 46(15):3275-82. PubMed ID: 12852757
[TBL] [Abstract][Full Text] [Related]
23. Protein-linked DNA strand breaks induced by NSC 314622, a novel noncamptothecin topoisomerase I poison.
Kohlhagen G; Paull KD; Cushman M; Nagafuji P; Pommier Y
Mol Pharmacol; 1998 Jul; 54(1):50-8. PubMed ID: 9658189
[TBL] [Abstract][Full Text] [Related]
24. Synthesis of new indeno[1,2-c]isoquinolines: cytotoxic non-camptothecin topoisomerase I inhibitors.
Cushman M; Jayaraman M; Vroman JA; Fukunaga AK; Fox BM; Kohlhagen G; Strumberg D; Pommier Y
J Med Chem; 2000 Oct; 43(20):3688-98. PubMed ID: 11020283
[TBL] [Abstract][Full Text] [Related]
25. An overview on the development of new potentially active camptothecin analogs against cancer.
Chazin Ede L; Reis Rda R; Junior WT; Moor LF; Vasconcelos TR
Mini Rev Med Chem; 2014; 14(12):953-62. PubMed ID: 25355593
[TBL] [Abstract][Full Text] [Related]
26. Clinical and pharmacologic evaluation of two dosing schedules of indotecan (LMP400), a novel indenoisoquinoline, in patients with advanced solid tumors.
Kummar S; Chen A; Gutierrez M; Pfister TD; Wang L; Redon C; Bonner WM; Yutzy W; Zhang Y; Kinders RJ; Ji J; Allen D; Covey JM; Eiseman JL; Holleran JL; Beumer JH; Rubinstein L; Collins J; Tomaszewski J; Parchment R; Pommier Y; Doroshow JH
Cancer Chemother Pharmacol; 2016 Jul; 78(1):73-81. PubMed ID: 27169793
[TBL] [Abstract][Full Text] [Related]
27. Differential and common DNA repair pathways for topoisomerase I- and II-targeted drugs in a genetic DT40 repair cell screen panel.
Maede Y; Shimizu H; Fukushima T; Kogame T; Nakamura T; Miki T; Takeda S; Pommier Y; Murai J
Mol Cancer Ther; 2014 Jan; 13(1):214-20. PubMed ID: 24130054
[TBL] [Abstract][Full Text] [Related]
28. Genomic profiling in CEPH cell lines distinguishes between the camptothecins and indenoisoquinolines.
Watson VG; Hardison NE; Harris T; Motsinger-Reif A; McLeod HL
Mol Cancer Ther; 2011 Oct; 10(10):1839-45. PubMed ID: 21750217
[TBL] [Abstract][Full Text] [Related]
29. Protracted dosing of the lipophilic camptothecin analogue AR-67 in non-small cell lung cancer xenografts and humans.
Tsakalozou E; Adane ED; Liang Y; Arnold SM; Leggas M
Cancer Chemother Pharmacol; 2014 Jul; 74(1):45-54. PubMed ID: 24807458
[TBL] [Abstract][Full Text] [Related]
30. Platinated DNA adducts enhance poisoning of DNA topoisomerase I by camptothecin.
van Waardenburg RC; de Jong LA; van Eijndhoven MA; Verseyden C; Pluim D; Jansen LE; Bjornsti MA; Schellens JH
J Biol Chem; 2004 Dec; 279(52):54502-9. PubMed ID: 15471886
[TBL] [Abstract][Full Text] [Related]
31. Antitumor activity of 7-[2-(N-isopropylamino)ethyl]-(20S)-camptothecin, CKD602, as a potent DNA topoisomerase I inhibitor.
Lee JH; Lee JM; Kim JK; Ahn SK; Lee SJ; Kim MY; Jew SS; Park JG; Hong CI
Arch Pharm Res; 1998 Oct; 21(5):581-90. PubMed ID: 9875499
[TBL] [Abstract][Full Text] [Related]
32. New Topoisomerase I mutations are associated with resistance to camptothecin.
Gongora C; Vezzio-Vie N; Tuduri S; Denis V; Causse A; Auzanneau C; Collod-Beroud G; Coquelle A; Pasero P; Pourquier P; Martineau P; Del Rio M
Mol Cancer; 2011 May; 10():64. PubMed ID: 21619602
[TBL] [Abstract][Full Text] [Related]
33. New strategies in the discovery of novel non-camptothecin topoisomerase I inhibitors.
Sheng C; Miao Z; Zhang W
Curr Med Chem; 2011; 18(28):4389-409. PubMed ID: 21861816
[TBL] [Abstract][Full Text] [Related]
34. Activity of a novel camptothecin analogue, homocamptothecin, in camptothecin-resistant cell lines with topoisomerase I alterations.
Urasaki Y; Takebayashi Y; Pommier Y
Cancer Res; 2000 Dec; 60(23):6577-80. PubMed ID: 11118036
[TBL] [Abstract][Full Text] [Related]
35. Chimmitecan, a novel 9-substituted camptothecin, with improved anticancer pharmacologic profiles in vitro and in vivo.
Huang M; Gao H; Chen Y; Zhu H; Cai Y; Zhang X; Miao Z; Jiang H; Zhang J; Shen H; Lin L; Lu W; Ding J
Clin Cancer Res; 2007 Feb; 13(4):1298-307. PubMed ID: 17287296
[TBL] [Abstract][Full Text] [Related]
36. In vivo antitumor activity of two new seven-substituted water-soluble camptothecin analogues.
Emerson DL; Besterman JM; Brown HR; Evans MG; Leitner PP; Luzzio MJ; Shaffer JE; Sternbach DD; Uehling D; Vuong A
Cancer Res; 1995 Feb; 55(3):603-9. PubMed ID: 7834631
[TBL] [Abstract][Full Text] [Related]
37. Relationship of DNA damage signaling to DNA replication following treatment with DNA topoisomerase inhibitors camptothecin/topotecan, mitoxantrone, or etoposide.
Zhao H; Rybak P; Dobrucki J; Traganos F; Darzynkiewicz Z
Cytometry A; 2012 Jan; 81(1):45-51. PubMed ID: 22140093
[TBL] [Abstract][Full Text] [Related]
38. PARP-1-dependent RND1 transcription induced by topoisomerase I cleavage complexes confers cellular resistance to camptothecin.
Mouly L; Mamouni K; Gence R; Cristini A; Cherier J; Castinel A; Legrand M; Favre G; Sordet O; Monferran S
Cell Death Dis; 2018 Sep; 9(9):931. PubMed ID: 30209297
[TBL] [Abstract][Full Text] [Related]
39. Exploring DNA topoisomerase I ligand space in search of novel anticancer agents.
Drwal MN; Agama K; Wakelin LP; Pommier Y; Griffith R
PLoS One; 2011; 6(9):e25150. PubMed ID: 21966440
[TBL] [Abstract][Full Text] [Related]
40. Overcoming Resistance to DNA-Targeted Agents by Epigenetic Activation of Schlafen 11 (
Tang SW; Thomas A; Murai J; Trepel JB; Bates SE; Rajapakse VN; Pommier Y
Clin Cancer Res; 2018 Apr; 24(8):1944-1953. PubMed ID: 29391350
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]